*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.
Pfizer's strategic maneuvers, including cost-cutting measures and a focus on commercial execution, have set the stage for its upcoming earnings announcement on November 4, 2025. The pharmaceutical giant recently raised its full-year profit guidance, buoyed by a robust second-quarter performance that exceeded Wall Street's expectations, with earnings per share (EPS) reaching $0.92. As Pfizer prepares to report its third-quarter results, analysts are eyeing an EPS estimate of $0.64 and revenue of $16.55 billion. However, the whisper number suggests a more optimistic EPS of $0.79, reflecting heightened investor expectations following Pfizer's reaffirmation of its 2025 revenue guidance between $61 billion and $64 billion. Despite challenges such as patent expirations and pricing pressures, Pfizer's market cap of approximately $140.8 billion underscores its resilience and strategic foresight. The recent uptick in share price, driven by the Seagen integration and Metsera acquisition, further signals a positive shift in market sentiment, as investors anticipate continued strong performance from Pfizer's diversified portfolio.
Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.
Website: https://www.pfizer.com
Average Sentiment Score:
Overall Sentiment: